These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28176482)

  • 1. High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure.
    Hammadah M; Kalogeropoulos AP; Georgiopoulou VV; Weber M; Wu Y; Hazen SL; Butler J; Tang WHW
    Eur J Heart Fail; 2017 Jun; 19(6):748-755. PubMed ID: 28176482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure.
    Tang WH; Wu Y; Mann S; Pepoy M; Shrestha K; Borowski AG; Hazen SL
    Circ Heart Fail; 2011 Jan; 4(1):59-64. PubMed ID: 21062973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of High-Density Lipoprotein-Associated Arylesterase Activity to Systolic Heart Failure in Patients with and without Type 2 Diabetes.
    Li C; Chen JW; Ding FH; Shen Y; Liu ZH; Wang F; Zhang RY; Shen WF; Lu L; Wang XQ
    Sci Rep; 2019 Apr; 9(1):5979. PubMed ID: 30979955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metrics of High-Density Lipoprotein Function and Hospital Mortality in Acute Heart Failure Patients.
    Potočnjak I; Degoricija V; Trbušić M; Terešak SD; Radulović B; Pregartner G; Berghold A; Tiran B; Marsche G; Frank S
    PLoS One; 2016; 11(6):e0157507. PubMed ID: 27304214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk.
    Tang WH; Hartiala J; Fan Y; Wu Y; Stewart AF; Erdmann J; Kathiresan S; ; Roberts R; McPherson R; Allayee H; Hazen SL
    Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2803-12. PubMed ID: 22982463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of High-Density Lipoprotein-Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease.
    Husni ME; Wilson Tang WH; Lucke M; Chandrasekharan UM; Brennan DM; Hazen SL
    Arthritis Rheumatol; 2018 Aug; 70(8):1240-1250. PubMed ID: 29569857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between inflammatory markers and serum paraoxonase and arylesterase activities in the general population: a cross-sectional study.
    Meisinger C; Freuer D; Bub A; Linseisen J
    Lipids Health Dis; 2021 Jul; 20(1):81. PubMed ID: 34332593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.
    McCullough PA; Barnard D; Clare R; Ellis SJ; Fleg JL; Fonarow GC; Franklin BA; Kilpatrick RD; Kitzman DW; O'Connor CM; Piña IL; Thadani U; Thohan V; Whellan DJ;
    Clin Cardiol; 2013 Oct; 36(10):611-20. PubMed ID: 23929781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Hospitalization for Heart Failure in Outpatients With Stable Coronary Artery Disease: Determinants, Role of Incident Myocardial Infarction, and Prognosis.
    Lamblin N; Meurice T; Tricot O; de Groote P; Lemesle G; Bauters C
    J Card Fail; 2018 Dec; 24(12):815-822. PubMed ID: 30296582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease.
    Kennedy DJ; Tang WH; Fan Y; Wu Y; Mann S; Pepoy M; Hazen SL
    J Am Heart Assoc; 2013 Apr; 2(2):e000104. PubMed ID: 23557751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M; Akca R; Sarandol E; Dilek K
    J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical variables.
    Toledo CC; Vellosa Schwartzmann P; Miguel Silva L; da Silva Ferreira G; Bianchini Cardoso F; Citelli Ribeiro V; Paim LR; Antunes-Correa LM; Carvalho Sposito A; Matos Souza JR; Modolo R; Nadruz W; Fernandes de Carvalho LS; Coelho-Filho OR
    ESC Heart Fail; 2021 Jun; 8(3):2133-2143. PubMed ID: 33734611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of High-Density Lipoprotein Parameters and Risk of Heart Failure: A Multicohort Analysis.
    Pandey A; Patel KV; Segar MW; Shapiro MD; Ballantyne CM; Virani SS; Nambi V; Michos ED; Blaha MJ; Nasir K; Cainzos-Achirica M; Ayers CR; Westenbrink BD; Flores-Guerrero JL; Bakker SJL; Connelly MA; Dullaart RPF; Rohatgi A
    JACC Heart Fail; 2024 Jul; 12(7):1242-1253. PubMed ID: 38752934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: Results of the IN-HF (Italian Network on Heart Failure) Outcome registry.
    Targher G; Dauriz M; Tavazzi L; Temporelli PL; Lucci D; Urso R; Lecchi G; Bellanti G; Merlo M; Rossi A; Maggioni AP;
    Int J Cardiol; 2016 Jan; 203():587-93. PubMed ID: 26574932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.
    Agarwala A; Pokharel Y; Saeed A; Sun W; Virani SS; Nambi V; Ndumele C; Shahar E; Heiss G; Boerwinkle E; Konety S; Hoogeveen RC; Ballantyne CM
    Atherosclerosis; 2017 Jul; 262():131-137. PubMed ID: 28554015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure.
    Banach M; Bhatia V; Feller MA; Mujib M; Desai RV; Ahmed MI; Guichard JL; Aban I; Love TE; Aronow WS; White M; Deedwania P; Fonarow G; Ahmed A
    Am J Cardiol; 2011 Apr; 107(8):1208-14. PubMed ID: 21296319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density lipoprotein cholesterol levels and prognosis in advanced heart failure.
    Mehra MR; Uber PA; Lavie CJ; Milani RV; Park MH; Ventura HO
    J Heart Lung Transplant; 2009 Sep; 28(9):876-80. PubMed ID: 19716038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired High-Density Lipoprotein Function in Patients With Heart Failure.
    Emmens JE; Jia C; Ng LL; van Veldhuisen DJ; Dickstein K; Anker SD; Lang CC; Filippatos G; Cleland JGF; Metra M; Voors AA; de Boer RA; Tietge UJF
    J Am Heart Assoc; 2021 May; 10(9):e019123. PubMed ID: 33870728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.
    Chirinos JA; Zhao L; Jia Y; Frej C; Adamo L; Mann D; Shewale SV; Millar JS; Rader DJ; French B; Brandimarto J; Margulies KB; Parks JS; Wang Z; Seiffert DA; Fang J; Sweitzer N; Chistoffersen C; Dahlbäck B; Car BD; Gordon DA; Cappola TP; Javaheri A
    Circulation; 2020 May; 141(18):1463-1476. PubMed ID: 32237898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: A pilot study.
    Cervellati C; Trentini A; Romani A; Bellini T; Bosi C; Ortolani B; Zurlo A; Passaro A; Seripa D; Zuliani G
    J Neurochem; 2015 Oct; 135(2):395-401. PubMed ID: 26178739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.